Contributions of Clinical Obesity and Preclinical Obesity to the All‐Cause Mortality Risk: Findings From the UK Biobank Cohort

作者：Ming Xu, Menghan Li, Yawen Zhang, Lianxi Li, Yun Shen, Gang Hu · 发表于：Diabetes/Metabolism Research and Reviews · 年份：2025 · DOI：10.1002/dmrr.70095 · 被引用次数：9 · 研究领域：Bariatric Surgery and Outcomes、Adipokines, Inflammation, and Metabolic Diseases、Obesity and Health Practices

BACKGROUND: The definition of clinical obesity was newly announced. The aim of our study was to investigate the association of preclinical obesity and clinical obesity either at baseline or determined during follow-ups with the risk of all-cause mortality. METHODS: Data were collected from 232,721 participants in the UK Biobank. Dysfunctions caused by obesity, in combination with an excess of anthropometric parameters, were used to diagnose clinical obesity. Participants were categorised into six clusters according to their baseline and follow-up dysfunction status. Time-dependent Cox proportional hazards regression was used to compare hazard ratios (HRs) for mortality across six clusters. RESULTS: In a total of 19,704 deaths over a mean follow-up of 13.4 years, participants in Cluster 6 (clinical obesity at baseline; HR = 2.30, 95% CI: 2.16-2.44) and Cluster 3 (non-obesity with baseline dysfunctions; HR = 2.02, 95% CI: 1.85-2.20) exhibited the highest multivariable-adjusted mortality risk compared with participants without obesity and dysfunction at baseline and during follow-up (Cluster 1). This was followed by participants in Cluster 2 (non-obesity without baseline but with follow-up dysfunctions; HR = 1.99, 95% CI: 1.88-2.10), Cluster 5 (preclinical obesity with follow-up dysfunctions; HR = 1.97, 95% CI: 1.87-2.07), and Cluster 4 (preclinical obesity without follow-up dysfunctions; HR = 1.15, 95% CI: 1.09-1.22). Subgroup analyses showed consistently higher mortality risks...